{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-019153","form_type":"8-K","ticker":"IRD","cik":"0001228627","company_name":"Opus Genetics, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.750270+00:00","generated_at":"2026-05-21T04:34:15.375075+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Opus Genetics Q1 net loss $8.2M; cash $41.8M; LCA5 gene therapy shows sustained 12-month efficacy","bullets":["Net loss of $8.2M ($0.24 per share) vs $7.1M ($0.29) in Q1 2024.","Cash and equivalents $41.8M; management expects runway into Q2 2026.","License revenue from Viatris was $4.4M, up from $1.7M YoY, primarily R&D reimbursement.","OPGx-LCA5 Phase 1/2 data at ARVO show durable efficacy at 12 months; pediatric cohort enrollment started.","Topline data for LYNX-2 (dim light) and VEGA-3 (presbyopia) Phase 3 trials expected mid-2025 and H1 2025, respectively."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-019153","json":"https://secwatch.observer/filing/0001140361-25-019153.json","markdown":"https://secwatch.observer/filing/0001140361-25-019153.md","text":"https://secwatch.observer/filing/0001140361-25-019153.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125019153/0001140361-25-019153-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1228627/000114036125019153/ef20049034_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:34:15.375075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}